WILMINGTON, MA--(Marketwire - Apr 2, 2012) - Implant Sciences Corporation (OTCQB: [ IMSC ]) (PINKSHEETS: [ IMSC ]), a high technology supplier of systems and sensors for homeland security and defense markets, today announced that it has hired Cheryl Debelis to fill the newly created position of Marketing Programs Manager. She will manage the Company's stepped up efforts in marketing its new Quantum Sniffer™ QS-B220 benchtop explosives and narcotics trace detector, as well as its Quantum Sniffer QS-H150, which has already sold units collectively worth over $30 million.

Ms. Debelis brings her expertise in marketing analytics, branding, and project management to Implant Sciences. She was most recently Marketing Analyst at PC Connection, Inc., where she developed and conducted branding studies, competitor analyses, market research, and customer satisfaction surveys. Before joining PC Connection, she was Marketing Analyst at GT Solar, Inc. (now GT Advanced Technologies, Inc.). Ms. Debelis has an MBA and a BA in Economics from the Whittemore School of Business, University of New Hampshire. She also holds a BA in French from the University of New Hampshire.

"In the past year, we have introduced the QS-B220, greatly increased the size of our distribution channel, and increased the number of countries we have sold equipment to by more than a third," commented Implant Sciences President and CEO Glenn D. Bolduc. "Cheryl will be an important resource for Implant Sciences to build on these successes. Her skills in market research and analysis will increase our ability to identify the kinds of capabilities that make our products the choice of security experts around the world."

About Implant Sciences

Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosive and narcotics trace detection systems which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and the Company's QS-B220 bench-top explosives and narcotics trace detector has received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at [ www.implantsciences.com ]

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; that our success depends on our ability to obtain new patents and operate without infringing on the proprietary rights of others; that we may not obtain the patents we have applied for; that the validity and breadth of claims in technology patents involve complex legal and factual questions and, therefore, may be highly uncertain; that any patents we may obtain may be may be challenged and subsequently invalidated, that we may incur substantial costs in asserting our patent rights; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.